Mari Selvi

Loves to be happy

[LARVOL @Larvol]

Stay informed about key cancer awareness dates in 2026.

Our calendar includes all awareness months and important dates to remember.

Explore more about oncology conferences, top trials, and reactions from oncologists: https://t.co/ct6tMIQHii

#LARVOL #Oncology #CancerCare #CancerAwarenes #BreastCancer #BCSM #LungCancer #LCSM #GICancer #GICSM #GUCancer #GUCSM #Melanoma #Lymphoma #Leukemia #MultipleMyeloma #HEMSM #MMSM #LEUSM #LYMSM #HeadAndNeckCancer #KindneyCancer #ColorectalCancer

[LARVOL @Larvol]

Plan your 2026 conference schedule better with
@Larvol.

Here is our list of the Top 30 Oncology Conferences worldwide. Explore more about oncology conferences, top trials, and reactions from oncologists: https://t.co/ct6tMIQHii

#LARVOL #Oncology #CancerResearch #CancerData #CancerCare #OncologyUpdates #OncologyConferences #OncologyInsights #GI26 #GU26 #ASCO26 #EHA26 #AACR26 #ESMO26 #SITC26 #ASH26 #SABCS26 #2026Events #MedicalConferences

The conferences: @ASCO | @ASH_hematology | @SABCSSanAntonio | @EHA_Hematology | @myESMO | @sitcancer | @IASLC | @SocietyofHemOnc | @AACR

[LARVOL @Larvol]

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

https://t.co/7ae6QZWjOy

Learn more 👉 https://t.co/LZRB9KrUtM

#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #FDA #FDAApproval #Neurofibromas

[LARVOL @Larvol]

A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster

https://t.co/1CKjj6oDfa

Learn more 👉 https://t.co/xbf5hOaFku

#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #FDA #FDAApproval

[LARVOL @Larvol]

Ahead of the European Lung Cancer Congress (ELCC) 2026, we asked leading AI models to forecast outcomes for high-impact lung cancer trials, before any numerical results are released.

We compared predictions across models to generate an AI consensus on expected efficacy signals across NSCLC and ES-SCLC, covering key endpoints including PFS, OS, and EFS.

Each forecast includes: hazard ratios, statistical significance (p < 0.05: Yes/No), median survival estimates, and a predicted Kaplan–Meier curve showing how outcomes may separate over time.

Highlights:
NSCLC

HARMONi: Ivonescimab + chemotherapy projected strong PFS benefit
▶️ AI consensus PFS HR: 0.36

KEYNOTE-671: Perioperative pembrolizumab expected to sustain benefit at long-term follow-up
▶️ EFS HR: 0.59 | OS HR: 0.73

TOP: Osimertinib + chemotherapy predicted to improve outcomes vs osimertinib alone
▶️ PFS HR: 0.65

OptiTROP-Lung03: Sac-TMT projected to show meaningful OS benefit
▶️ OS HR: 0.59

ES-SCLC
IMpower133: Long-term follow-up expected to maintain immunotherapy benefit
▶️ OS HR: 0.79 | PFS HR: 0.80

CAPSTONE-1: Adebrelimab + chemotherapy forecast to sustain survival advantage
▶️ OS HR: 0.76

Mixed signals

EMPOWER-Lung 1: Cemiplimab monotherapy predicted to maintain durable survival gains
▶️ OS HR: 0.61

LATIFY: Limited benefit expected for ceralasertib + durvalumab
▶️ OS HR: 0.98 (not significant)

Across trials, the AI consensus points to continued durability of immunotherapy benefits, incremental gains from combination strategies, and variable outcomes in targeted therapy settings.

Which ELCC 2026 results do you expect will beat or fall short of these forecasts?

Explore more insights and conference data from #ELCC26 👉 https://t.co/PuWKbMIQiA

#LARVOL #ELCC2026 #LungCancer #LCSM #NSCLC #SCLC #ESSCLC #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @Tony_Calles | @FordePatrick | @HHorinouchi | @BalazsHalmosMD | @DrSanjayPopat

[LARVOL @Larvol]

Our top highlights from @ASCO 2025.

Follow us for the latest oncology updates: https://t.co/1AuNSQx3PR

#LARVOL #ASCO25 #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsights #ASCO2025 | @BrunoLarvol | @one_interrobang | @GIMedOnc | @nicogirardcurie | @Timothee_MD | @StephenVLiu | @DrYukselUrun | @PatelOncology | @mwschoen | @PTarantinoMD | @DrMLChua | @realbowtiedoc

[LARVOL @Larvol]

Post - #ASCO25 | LARVOL CLIN - Building in public: Episode 35 https://t.co/q6u8IA3XAk

[LARVOL @Larvol]

Plan your 2025 conference schedule better with @Larvol. Here is our list of the Top 25 Oncology Conferences worldwide.

Follow us for the latest updates: https://t.co/bW8jRb3bvS

#LARVOL #Oncology #CancerResearch #CancerData #CancerCare #OncologyUpdates #OncologyConferences #OncologyInsights #GI25 #GU25 #ASCO25 #EHA25 #AACR25 #ESMO25 #SITC25 #ASH25 #SABCS25 #2025Events #MedicalConferences

The conferences: @ASCO | @ASH_hematology | @SABCSSanAntonio | @EHA_Hematology | @myESMO
| @sitcancer | @IASLC | @SocietyofHemOnc | @AACR

[LARVOL @Larvol]

@Larvol is heading to the @EHA_Hematology 2025 in Milan!

Connect with Bruno Larvol (@brunolarvol), CEO, and Kimon Lounis, Business Development Manager, at the conference.

Looking forward to connecting with the hematology community, discussing the latest research, and exploring new insights.

See you there!

Get the latest #EHA25 updates: https://t.co/GlFVhoEqda

#LARVOL #CancerResearch #Hematology #Oncology #CancerData #CancerData #OncologyInsights #ClinicalTrials

[LARVOL @Larvol]

Top #LungCancer Oncologists from @ASCO 2025.

Follow us for more #ASCO25 updates: https://t.co/1AuNSQxBFp

#LARVOL #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsights #ASCO2025 | @ADesaiMD | @StephenVLiu | @HHorinouchi | @diegoadiazg | @HerediaOncologo | @GlopesMd | @lungoncdoc | @CharuAggarwalMD | @DrRiyazShah | @FordePatrick

[LARVOL @Larvol]

Top #BreastCancer Oncologists from @ASCO 2025.

Follow us for more #ASCO25 updates: https://t.co/1AuNSQxBFp

#LARVOL #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsights #ASCO2025 | @PTarantinoMD | @dr_yakupergun | @kazuki_nozawa | @DrHBurstein | @Dr_Oncologista | @DrSGraff | @Dr_RShatsky | @drsarahsam | @matteolambe | @DrRBarroso

[LARVOL @Larvol]

Top #GUCancer Oncologists from @ASCO 2025.

Follow us for more #ASCO25 updates: https://t.co/1AuNSQx3PR

#LARVOL #GenitourinaryCancer #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsights #ASCO2025 | @DrChoueiri | @neerajaiims | @AndreaNecchi | @tompowles1 | @drenriquegrande | @DrYukselUrun | @nataliagandur | @TapiaJC1 | @DrKarineTawagi | @MikeSerzanMD

[LARVOL @Larvol]

Top #GICancer Oncologists from @ASCO 2025.

Follow us for more #ASCO25 updates: https://t.co/1AuNSQxBFp

#LARVOL #GastrointestinalCancer #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsights #ASCO2025 | @GillSharlene | @GIMedOnc | @ArndtVogel | @Erman_Akkus | @pashtoonkasi | @jgong15 | @oncology_bg | @ryanhuey | @FernandoOnco | @UGrewalMD

[LARVOL @Larvol]

Top #HemOnc Oncologists from @ASCO 2025.

Follow us for more #ASCO25 updates: https://t.co/1AuNSQxBFp

#LARVOL #Hematology #BloodCancer #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsights #ASCO2025 | @mtmdphd | @VincentRK | @AuclairDan | @bdermanmd | @szusmani | @HadidiSamer | @TalhaBadarMD | @Rfonsi1 | @doctorpemm | @RahulBanerjeeMD

[LARVOL @Larvol]

Top Women Oncologists from @ASCO 2025.

Follow us for more #ASCO25 updates: https://t.co/1AuNSQxBFp

#LARVOL #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsights #ASCO2025 | @GillSharlene | @Dr_Oncologista | @DrKatyMoore | @DrSGraff | @nataliagandur | @CharuAggarwalMD | @Dr_RShatsky | @DrKarineTawagi | @TiansterZhang | @drsarahsam

[LARVOL @Larvol]

Here are the top trials from day 4 of @ASCO 2025.

Follow us and get the latest #ASCO25 updates: https://t.co/051z3BNE4z

#LARVOL #ASCO2025 #CancerResearch #Oncology #ClinicalTrials #CancerData #CancerCare | @PTarantinoMD | @drsarahsam | @StephenVLiu | @Tony_Calles | @BalazsHalmosMD | @lungoncdoc | @matteolambe | @SuyogCancer

[LARVOL @Larvol]

✅ FDA Approval Alert! Darolutamide + ADT has been approved for metastatic hormone-sensitive prostate cancer (mHSPC) based on Phase III #ARANOTE trial data.

🧬 The combo reduced the risk of progression or death by 46% vs placebo + ADT (HR 0.54, P<0.0001). A major step forward in Prostate Cancer care.

Check out the previous FDA approvals: https://t.co/ajalVShfE3

#LARVOL #CancerResearch #Oncology #ClinicalTrials #CancerData #ProstateCancer #Oncology #mCSPC #CancerCare #OncologyInsight #PrecisionOncology | @ArndtVogel | @StephenVLiu | @CathyEngMD | @AaronGoodman33 | @neerajaiims | @PGrivasMDPhD | @DrMLChua | @YJanjigianMD | @agz_eriksson | @SuyogCancer

[LARVOL @Larvol]

@Larvol Quick Takes: At @ASCO 2025, Dr. Nicholas Hornstein (@GIMedOnc) talks to Bruno Larvol (@brunolarvol) about BREAKWATER.

Discover more about BREAKWATER: https://t.co/l4OIbjRqBQ

#LARVOL #ASCO25 #BREAKWATER #CRC #CancerResearch #Oncology #ClinicalTrials #CancerData #CancerCare #ASCO2025

[LARVOL @Larvol]

@Larvol Quick Takes: El Dr. Sergio Cifuentes (@Onco_Cifu88) nos comparte su perspectiva sobre el CHALLENGE Trial en cáncer colorrectal (CRC), directamente desde @ASCO 2025.

Descubra más sobre CHALLENGE: https://t.co/MtElgsZo3w

#LARVOL #ASCO25 #CHALLENGE #CRC #ColonCancer #CancerResearch #Oncology #ClinicalTrials #CancerData #CancerCare #ASCO2025 | Bruno Larvol (@brunolarvol)

[LARVOL @Larvol]

From connecting with oncology experts to diving into the latest breakthroughs in cancer research, we had a great time at @ASCO 2025!

Follow us for the latest oncology updates: https://t.co/1AuNSQx3PR

#LARVOL #ASCO25 #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsights #ASCO2025 | @BrunoLarvol | @one_interrobang | @GIMedOnc | @nicogirardcurie | @Timothee_MD | @StephenVLiu | @DrYukselUrun